Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oncology in 2012: from personalized medicine to precision medicine

Oncology in 2012: from personalized medicine to precision medicine Targ Oncol (2012) 7:211–212 DOI 10.1007/s11523-012-0238-5 EDITORIAL Oncology in 2012: from personalized medicine to precision medicine J. F. Morere Received: 28 October 2012 /Accepted: 29 October 2012 /Published online: 22 November 2012 Springer-Verlag France 2012 Although oncologists seem unable to name the new para- striking hazard ratio (HR) of 0.49 [3]. Regorafenib [4] offers digm of cancer treatment, a certain trend seems to take shape a new therapeutic option in metastatic colorectal cancers in in favor of the precision medicine. To paraphrase Mickael P. second-line treatment and in GIST. Cabozantinib, a new Link, President of the American Society of Clinical Oncol- potent inhibitor of VEGFR and MET and VEGFr2 [5], ogy, precision medicine identifies and makes the most of the shows promise in several tumor types, such as prostate, weaknesses of cancer genetics so that the tumoral breast, and hepatocarcinoma. Dabrafenib, a new anti-RAF growth can be stopped. Doubtless, major advances in agent can achieve an HR of 0.35 for progression-free sur- this oncologic medicine of precision have been observed vival in patients with metastatic melanoma [6]. throughout 2012. MEK blockade is one of the last novelties in signal- These advances have first of all affected the theranostics. ing. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Oncology in 2012: from personalized medicine to precision medicine

Morere, J.
Targeted Oncology , Volume 7 (4) – Nov 22, 2012
Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/oncology-in-2012-from-personalized-medicine-to-precision-medicine-m0TV8ZwF0p

References (8)

Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag France
Subject
Medicine & Public Health; Oncology; Biomedicine general
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-012-0238-5
pmid
23179557
Publisher site
See Article on Publisher Site

Abstract

Targ Oncol (2012) 7:211–212 DOI 10.1007/s11523-012-0238-5 EDITORIAL Oncology in 2012: from personalized medicine to precision medicine J. F. Morere Received: 28 October 2012 /Accepted: 29 October 2012 /Published online: 22 November 2012 Springer-Verlag France 2012 Although oncologists seem unable to name the new para- striking hazard ratio (HR) of 0.49 [3]. Regorafenib [4] offers digm of cancer treatment, a certain trend seems to take shape a new therapeutic option in metastatic colorectal cancers in in favor of the precision medicine. To paraphrase Mickael P. second-line treatment and in GIST. Cabozantinib, a new Link, President of the American Society of Clinical Oncol- potent inhibitor of VEGFR and MET and VEGFr2 [5], ogy, precision medicine identifies and makes the most of the shows promise in several tumor types, such as prostate, weaknesses of cancer genetics so that the tumoral breast, and hepatocarcinoma. Dabrafenib, a new anti-RAF growth can be stopped. Doubtless, major advances in agent can achieve an HR of 0.35 for progression-free sur- this oncologic medicine of precision have been observed vival in patients with metastatic melanoma [6]. throughout 2012. MEK blockade is one of the last novelties in signal- These advances have first of all affected the theranostics. ing.

Journal

Targeted Oncology – Springer Journals

Published: Nov 22, 2012

There are no references for this article.